European Journal of Cancer
Volume 41, Issue 6 , Pages 846-857 , April 2005

Functions and regulation of transforming growth factor-beta (TGF-β) in the prostate

Received 16 October 2004 ,Revised 24 October 2004 ,Accepted 2 December 2004.

References 

  1. Roberts AB, Sporn MB. The transforming growth factor beta. New York: Springer-Verlag; 1990;
  2. Sporn MB, Roberts AB. TGF-beta: problems and prospects. Cell Regul. 1990;1(12):875–882
  3. Wrana JL. TGF-beta receptors and signalling mechanisms. Miner Electrol Metab. 1998;24(2–3):120–130
  4. Massague J, Andres J, Attisano L, et al. TGF-beta receptors. Mol Reprod Dev. 1992;32(2):99–104
  5. Kretzschmar M, Massague J. SMADs: mediators and regulators of TGF-beta signaling. Curr Opin Genet Dev. 1998;8(1):103–111
  6. Massague J. TGFbeta signaling: receptors, transducers, and Mad proteins. Cell. 1996;85(7):947–950
  7. Liu F, Pouponnot C, Massague J. Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes. Genes Dev. 1997;11(23):3157–3167
  8. Wrana J, Pawson T. Signal transduction. Mad about SMADs. [news; comment] Nature. 1997;388(6637):28–29
  9. Miyazawa K, Shinozaki M, Hara T, et al. Two major Smad pathways in TGF-beta superfamily signalling. Genes Cells. 2002;7(12):1191–1204
  10. Yeh S, Sampson ER, Lee DK, et al. Functional analysis of androgen receptor N-terminal and ligand binding domain interacting coregulators in prostate cancer. J Formos Med Assoc. 2000;99(12):885–894
  11. So AI, Hurtado-Coll A, Gleave ME. Androgens and prostate cancer. World J Urol. 2003;21(5):325–337
  12. Kim IY, Ahn HJ, Zelner DJ, et al. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res. 1996;2(8):1255–1261
  13. Guo Y, Jacobs SC, Kyprianou N. Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer. Int J Cancer. 1997;71(4):573–579
  14. Williams RH, Stapleton AM, Yang G, et al. Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: an immunohistochemical study. Clin Cancer Res. 1996;2(4):635–640
  15. Guo Y, Kyprianou N. Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells. Cell Growth Differ. 1998;9(2):185–193
  16. Guo Y, Kyprianou N. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res. 1999;59(6):1366–1371
  17. Tang B, de Castro K, Barnes HE, et al. Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells. Cancer Res. 1999;59(19):4834–4842
  18. Eastham JA, Truong LD, Rogers E, et al. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest. 1995;73(5):628–635
  19. Henis YI, Moustakas A, Lin HY, et al. The types II and III transforming growth factor-beta receptors form homo-oligomers. J Cell Biol. 1994;126(1):139–154
  20. Luo K, Lodish HF. Signaling by chimeric erythropoietin-TGF-beta receptors: homodimerization of the cytoplasmic domain of the type I TGF-beta receptor and heterodimerization with the type II receptor are both required for intracellular signal transduction. Embo J. 1996;15(17):4485–4496
  21. Luo K, Lodish HF. Positive and negative regulation of type II TGF-beta receptor signal transduction by autophosphorylation on multiple serine residues. Embo J. 1997;16(8):1970–1981
  22. Lopez-Casillas F, Wrana JL, Massague J. Betaglycan presents ligand to the TGF beta signaling receptor. Cell. 1993;73(7):1435–1444
  23. Tsukazaki T, Chiang TA, Davison AF, et al. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell. 1998;95(6):779–791
  24. Miura S, Takeshita T, Asao H, et al. Hgs (Hrs), a FYVE domain protein, is involved in Smad signaling through cooperation with SARA. Mol Cell Biol. 2000;20(24):9346–9355
  25. Hocevar BA, Smine A, Xu XX, et al. The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway. Embo J. 2001;20(11):2789–2801
  26. Moskaluk CA, Hruban RH, Schutte M, et al. Genomic sequencing of DPC4 in the analysis of familial pancreatic carcinoma. Diagn Mol Pathol. 1997;6(2):85–90
  27. Wu RY, Zhang Y, Feng XH, et al. Heteromeric and homomeric interactions correlate with signaling activity and functional cooperativity of Smad3 and Smad4/DPC4. Mol Cell Biol. 1997;17(5):2521–2528
  28. Ten Dijke P, Goumans MJ, Itoh F, et al. Regulation of cell proliferation by Smad proteins. J Cell Physiol. 2002;191(1):1–16
  29. Liu X, Sun Y, Constantinescu SN, et al. Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. Proc Natl Acad Sci USA. 1997;94(20):10669–10674
  30. Yamamura Y, Hua X, Bergelson S, et al. Critical role of smads and AP-1 complex in TGF-{beta}-dependentapoptosis. J Biol Chem. 2000;
  31. Engel ME, McDonnell MA, Law BK, et al. Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription. J Biol Chem. 1999;274(52):37413–37420
  32. Adachi-Yamada T, Nakamura M, Irie K, et al. p38 mitogen-activated protein kinase can be involved in transforming growth factor beta superfamily signal transduction in Drosophila wing morphogenesis. Mol Cell Biol. 1999;19(3):2322–2329
  33. Atfi A, Djelloul S, Chastre E, et al. Evidence for a role of Rho-like GTPases and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in transforming growth factor beta-mediated signaling. J Biol Chem. 1997;272(3):1429–1432
  34. Axmann A, Seidel D, Reimann T, et al. Transforming growth factor-beta1-induced activation of the Raf-MEK-MAPK signaling pathway in rat lung fibroblasts via a PKC-dependent mechanism. Biochem Biophys Res Commun. 1998;249(2):456–460
  35. Brown JD, DiChiara MR, Anderson KR, et al. MEKK-1, a component of the stress (stress-activated protein kinase/c- Jun N-terminal kinase) pathway, can selectively activate Smad2-mediated transcriptional activation in endothelial cells. J Biol Chem. 1999;274(13):8797–8805
  36. Engel ME, Datta PK, Moses HL. Signal transduction by transforming growth factor-beta: a cooperative paradigm with extensive negative regulation. J Cell Biochem Suppl. 1998;31:111–122
  37. Lo RS, Chen YG, Shi Y, et al. The L3 loop: a structural motif determining specific interactions between SMAD proteins and TGF-beta receptors. Embo J. 1998;17(4):996–1005
  38. Dong C, Li Z, Alvarez R, et al. Microtubule binding to Smads may regulate TGF beta activity. Mol Cell. 2000;5(1):27–34
  39. Shi Y, Wang YF, Jayaraman L, et al. Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling. Cell. 1998;94(5):585–594
  40. Xiao Z, Liu X, Lodish HF. Importin beta mediates nuclear translocation of Smad 3. J Biol Chem. 2000;275(31):23425–23428
  41. Yagi K, Goto D, Hamamoto T, et al. Alternatively spliced variant of Smad2 lacking exon 3. Comparison with wild-type Smad2 and Smad3. J Biol Chem. 1999;274(2):703–709
  42. Kurisaki A, Kose S, Yoneda Y, et al. Transforming growth factor-beta induces nuclear import of Smad3 in an importin-beta1 and Ran-dependent manner. Mol Biol Cell. 2001;12(4):1079–1091
  43. Jonk LJ, Itoh S, Heldin CH, et al. Identification and functional characterization of a Smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-beta, activin, and bone morphogenetic protein-inducible enhancer. J Biol Chem. 1998;273(33):21145–21152
  44. Piek E, Heldin CH, Ten Dijke P. Specificity, diversity, and regulation in TGF-beta superfamily signaling. Faseb J. 1999;13(15):2105–2124
  45. Charng MJ, Kinnunen P, Hawker J, et al. FKBP-12 recognition is dispensable for signal generation by type I transforming growth factor-beta receptors. J Biol Chem. 1996;271(38):22941–22944
  46. Charng MJ, Zhang D, Kinnunen P, et al. A novel protein distinguishes between quiescent and activated forms of the type I transforming growth factor beta receptor. J Biol Chem. 1998;273(16):9365–9368
  47. Chen YG, Liu F, Massague J. Mechanism of TGFbeta receptor inhibition by FKBP12. Embo J. 1997;16(13):3866–3876
  48. Hu JS, Olson EN. Regulation of differentiation of the BC3H1 muscle cell line through cAMP-dependent and -independent pathways. J Biol Chem. 1988;263(36):19670–19677
  49. Ventura F, Liu F, Doody J, et al. Interaction of transforming growth factor-beta receptor I with farnesyl- protein transferase-alpha in yeast and mammalian cells. J Biol Chem. 1996;271(24):13931–13934
  50. Kawabata M, Imamura T, Miyazono K, et al. Interaction of the transforming growth factor-beta type I receptor with farnesyl-protein transferase-alpha. J Biol Chem. 1995;270(50):29628–29631
  51. Griswold-Prenner I, Kamibayashi C, Maruoka EM, et al. Physical and functional interactions between type I transforming growth factor beta receptors and Balpha, a WD-40 repeat subunit of phosphatase 2A. Mol Cell Biol. 1998;18(11):6595–6604
  52. Reddy KB, Karode MC, Harmony AK, et al. Interaction of transforming growth factor beta receptors with apolipoprotein J/clusterin. Biochemistry. 1996;35(1):309–314
  53. Leger JG, Montpetit ML, Tenniswood MP. Characterization and cloning of androgen-repressed mRNAs from rat ventral prostate. Biochem Biophys Res Commun. 1987;147(1):196–203
  54. Jin G, Howe PH. Transforming growth factor beta regulates clusterin gene expression via modulation of transcription factor c-Fos. Eur J Biochem. 1999;263(2):534–542
  55. Choy L, Derynck R. The type II transforming growth factor (TGF)-beta receptor-interacting protein TRIP-1 acts as a modulator of the TGF-beta response. J Biol Chem. 1998;273(47):31455–31462
  56. Perlman R, Schiemann WP, Brooks MW, et al. TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nat Cell Biol. 2001;3(8):708–714
  57. Hofmann TG, Stollberg N, Schmitz ML, et al. HIPK2 regulates transforming growth factor-beta-induced c-Jun NH (2)-terminal kinase activation and apoptosis in human hepatoma cells. Cancer Res. 2003;63(23):8271–8277
  58. Datta PK, Chytil A, Gorska AE, et al. Identification of STRAP, a novel WD domain protein in transforming growth factor-beta signaling. J Biol Chem. 1998;273(52):34671–34674
  59. Fynan TM, Reiss M. Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit Rev Oncog. 1993;4(5):493–540
  60. Markowitz SD, Roberts AB. Tumor suppressor activity of the TGF-beta pathway in human cancers. [see comments] Cytokine Growth Factor Rev. 1996;7(1):93–102
  61. Parsons R, Myeroff LL, Liu B, et al. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res. 1995;55(23):5548–5550
  62. Garrigue-Antar L, Munoz-Antonia T, Antonia SJ, et al. Missense mutations of the transforming growth factor beta type II receptor in human head and neck squamous carcinoma cells. Cancer Res. 1995;55(18):3982–3987
  63. Korc M. Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am. 1998;7(1):25–41
  64. Hata A, Shi Y, Massague J. TGF-beta signaling and cancer: structural and functional consequences of mutations in Smads. Mol Med Today. 1998;4(6):257–262
  65. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. [see comments] Science. 1995;268(5215):1336–1338
  66. Wang J, Sun L, Myeroff L, et al. Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J Biol Chem. 1995;270(37):22044–22049
  67. Chang J, Park K, Bang YJ, et al. Expression of transforming growth factor beta type II receptor reduces tumorigenicity in human gastric cancer cells. Cancer Res. 1997;57(14):2856–2859
  68. Sun L, Wu G, Willson JK, et al. Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem. 1994;269(42):26449–26455
  69. Robson CN, Gnanapragasam V, Byrne RL, et al. Transforming growth factor-beta1 up-regulates p15, p21 and p27 and blocks cell cycling in G1 in human prostate epithelium. J Endocrinol. 1999;160(2):257–266
  70. Li JM, Nichols MA, Chandrasekharan S, et al. Transforming growth factor beta activates the promoter of cyclin-dependent kinase inhibitor p15INK4B through an Sp1 consensus site. J Biol Chem. 1995;270(45):26750–26753
  71. Iavarone A, Massague J. E2F and histone deacetylase mediate transforming growth factor beta repression of cdc25A during keratinocyte cell cycle arrest. Mol Cell Biol. 1999;19(1):916–922
  72. Yagi K, Furuhashi M, Aoki H, et al. c-myc is a downstream target of the Smad pathway. J Biol Chem. 2002;277(1):854–861
  73. Seoane J, Pouponnot C, Staller P, et al. TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat Cell Biol. 2001;3(4):400–408
  74. Staller P, Peukert K, Kiermaier A, et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol. 2001;3(4):392–399
  75. Petritsch C, Beug H, Balmain A, et al. TGF-beta inhibits p70 S6 kinase via protein phosphatase 2A to induce G (1) arrest. Genes Dev. 2000;14(24):3093–3101
  76. Hung WC, Chang HC, Chuang LY. Transforming growth factor beta 1 potently activates CPP32-like proteases in human hepatoma cells. Cell Signal. 1998;10(7):511–515
  77. Shima Y, Nakao K, Nakashima T, et al. Activation of caspase-8 in transforming growth factor-beta-induced apoptosis of human hepatoma cells. Hepatology. 1999;30(5):1215–1222
  78. Schrantz N, Blanchard DA, Auffredou MT, et al. Role of caspases and possible involvement of retinoblastoma protein during TGFbeta-mediated apoptosis of human B lymphocytes. Oncogene. 1999;18(23):3511–3519
  79. Brown TL, Patil S, Basnett RK, et al. Caspase inhibitor BD-fmk distinguishes transforming growth factor beta-induced apoptosis from growth inhibition. Cell Growth Differ. 1998;9(10):869–875
  80. Brown TL, Patil S, Cianci CD, et al. Transforming growth factor beta induces caspase 3-independent cleavage of alphaII-spectrin (alpha-fodrin) coincident with apoptosis. J Biol Chem. 1999;274(33):23256–23262
  81. Chipuk JE, Bhat M, Hsing AY, et al. Bcl-xL blocks transforming growth factor-beta 1-induced apoptosis by inhibiting cytochrome c release and not by directly antagonizing Apaf-1-dependent caspase activation in prostate epithelial cells. J Biol Chem. 2001;276(28):26614–26621
  82. Ahmed MM, Alcock RA, Chendil D, et al. Restoration of transforming growth factor-beta signaling enhances radiosensitivity by altering the Bcl-2/Bax ratio in the p53 mutant pancreatic cancer cell line MIA PaCa-2. J Biol Chem. 2002;277(3):2234–2246
  83. Jang CW, Chen CH, Chen CC, et al. TGF-beta induces apoptosis through Smad-mediated expression of DAP-kinase. Nat Cell Biol. 2002;4(1):51–58
  84. Yamaguchi K, Nagai S, Ninomiya-Tsuji J, et al. XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway. Embo J. 1999;18(1):179–187
  85. Saile B, Matthes N, El Armouche H, et al. The bcl, NFkappaB and p53/p21WAF1 systems are involved in spontaneous apoptosis and in the anti-apoptotic effect of TGF-beta or TNF-alpha on activated hepatic stellate cells. Eur J Cell Biol. 2001;80(8):554–561
  86. Larisch-Bloch S, Danielpour D, Roche NS, et al. Selective loss of the transforming growth factor-beta apoptotic signaling pathway in mutant NRP-154 rat prostatic epithelial cells. Cell Growth Differ. 2000;11(1):1–10
  87. Larisch S, Yi Y, Lotan R, et al. A novel mitochondrial septin-like protein, ARTS, mediates apoptosis dependent on its P-loop motif. Nat Cell Biol. 2000;2(12):915–921
  88. English HF, Santen RJ, Isaacs JT. Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate. 1987;11(3):229–242
  89. Hayward SW, Brody JR, Cunha GR. An edgewise look at basal epithelial cells: three-dimensional views of the rat prostate, mammary gland and salivary gland. Differentiation. 1996;60(4):219–227
  90. Hayward SW, Baskin LS, Haughney PC, et al. Epithelial development in the rat ventral prostate, anterior prostate and seminal vesicle. Acta Anat. 1996;155(2):81–93
  91. Kim IY, Ahn HJ, Zelner DJ, et al. Expression and localization of transforming growth factor-beta receptors type I and type II in the rat ventral prostate during regression. Mol Endocrinol. 1996;10(1):107–115
  92. Kyprianou N, Isaacs JT. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology. 1988;122(2):552–562
  93. Kyprianou N, Isaacs JT. Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol. 1989;3(10):1515–1522
  94. Martikainen P, Kyprianou N, Isaacs JT. Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells. Endocrinology. 1990;127(6):2963–2968
  95. Lucia MS, Sporn MB, Roberts AB, et al. The role of transforming growth factor-beta1, -beta2, and -beta3 in androgen-responsive growth of NRP-152 rat prostatic epithelial cells. J Cell Physiol. 1998;175(2):184–192
  96. Chipuk JE, Cornelius SC, Pultz NJ, et al. The androgen receptor represses transforming growth factor-beta signaling through interaction with Smad3. J Biol Chem. 2002;277(2):1240–1248
  97. Hsing AY, Kadomatsu K, Bonham MJ, et al. Regulation of apoptosis induced by transforming growth factor-beta1 in nontumorigenic rat prostatic epithelial cell lines. Cancer Res. 1996;56(22):5146–5149
  98. Kundu SD, Kim IY, Yang T, et al. Absence of proximal duct apoptosis in the ventral prostate of transgenic mice carrying the C3 (1)-TGF-beta type II dominant negative receptor. Prostate. 2000;43(2):118–124
  99. Kim IY, Ahn HJ, Zelner DJ, et al. Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells. Cancer Res. 1996;56(1):44–48
  100. Danielpour D, Kadomatsu K, Anzano MA, et al. Development and characterization of nontumorigenic and tumorigenic epithelial cell lines from rat dorsal–lateral prostate. Cancer Res. 1994;54(13):3413–3421
  101. Danielpour D. Transdifferentiation of NRP-152 rat prostatic basal epithelial cells toward a luminal phenotype: regulation by glucocorticoid, insulin-like growth factor-I and transforming growth factor-beta. J Cell Sci. 1999;112(Pt 2):169–179
  102. Hayward SW, Haughney PC, Lopes ES, et al. The rat prostatic epithelial cell line NRP-152 can differentiate in vivo in response to its stromal environment. Prostate. 1999;39(3):205–212
  103. Song K, Cornelius SC, Danielpour D. Development and characterization of DP-153, a nontumorigenic prostatic cell line that undergoes malignant transformation by expression of dominant-negative transforming growth factor beta receptor type II. Cancer Res. 2003;63(15):4358–4367
  104. Tu WH, Thomas TZ, Masumori N, et al. The loss of TGF-beta signaling promotes prostate cancer metastasis. Neoplasia. 2003;5(3):267–277
  105. Hayward SW, Rosen MA, Cunha GR. Stromal–epithelial interactions in the normal and neoplastic prostate. Br J Urol. 1997;79(Suppl 2):18–26
  106. Cunha GR, Hayward SW, Wang YZ. Role of stroma in carcinogenesis of the prostate. Differentiation. 2002;70(9–10):473–485
  107. Rowley DR. What might a stromal response mean to prostate cancer progression?. Cancer Metastasis Rev. 1998;17(4):411–419
  108. Peehl DM, Sellers RG. Induction of smooth muscle cell phenotype in cultured human prostatic stromal cells. Exp Cell Res. 1997;232(2):208–215
  109. Bhowmick NA, Chytil A, Plieth D, et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science. 2004;303(5659):848–851
  110. Hayward SW, Baskin LS, Haughney PC, et al. Stromal development in the ventral prostate, anterior prostate and seminal vesicle of the rat. Acta Anat. 1996;155(2):94–103
  111. Gerdes MJ, Dang TD, Larsen M, et al. Transforming growth factor-beta1 induces nuclear to cytoplasmic distribution of androgen receptor and inhibits androgen response in prostate smooth muscle cells. Endocrinology. 1998;139(8):3569–3577
  112. Salm SN, Koikawa Y, Ogilvie V, et al. Generation of active TGF-beta by prostatic cell cocultures using novel basal and luminal prostatic epithelial cell lines. J Cell Physiol. 2000;184(1):70–79
  113. Kyprianou N, Isaacs JT. Identification of a cellular receptor for transforming growth factor-beta in rat ventral prostate and its negative regulation by androgens. Endocrinology. 1988;123(4):2124–2131
  114. Nishi N, Oya H, Matsumoto K, et al. Changes in gene expression of growth factors and their receptors during castration-induced involution and androgen-induced regrowth of rat prostates. Prostate. 1996;28(3):139–152
  115. Brodin G, ten Dijke P, Funa K, et al. Increased Smad expression and activation are associated with apoptosis in normal and malignant prostate after castration. Cancer Res. 1999;59(11):2731–2738
  116. Hayes SA, Zarnegar M, Sharma M, et al. SMAD3 represses androgen receptor-mediated transcription. Cancer Res. 2001;61(5):2112–2118
  117. Kang HY, Lin HK, Hu YC, et al. From transforming growth factor-beta signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. Proc Natl Acad Sci USA. 2001;98(6):3018–3023
  118. Kang HY, Huang KE, Chang SY, et al. Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4. J Biol Chem. 2002;277(46):43749–43756
  119. Bruckheimer EM, Kyprianou N. Dihydrotestosterone enhances transforming growth factor-beta-induced apoptosis in hormone-sensitive prostate cancer cells. Endocrinology. 2001;142(6):2419–2426
  120. Bruckheimer EM, Kyprianou N. Bcl-2 antagonizes the combined apoptotic effect of transforming growth factor-beta and dihydrotestosterone in prostate cancer cells. Prostate. 2002;53(2):133–142
  121. Carey JL, Sasur LM, Kawakubo H, et al. Mutually antagonistic effects of androgen and activin in the regulation of prostate cancer cell growth. Mol Endocrinol. 2004;18(3):696–707
  122. Linja MJ, Savinainen KJ, Saramaki OR, et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001;61(9):3550–3555
  123. Kuiper GG, Brinkmann AO. Phosphotryptic peptide analysis of the human androgen receptor: detection of a hormone-induced phosphopeptide. Biochemistry. 1995;34(6):1851–1857
  124. Hsiao PW, Lin DL, Nakao R, et al. The linkage of Kennedy’s neuron disease to ARA24, the first identified androgen receptor polyglutamine region-associated coactivator. J Biol Chem. 1999;274(29):20229–20234
  125. Hsiao PW, Chang C. Isolation and characterization of ARA160 as the first androgen receptor N-terminal-associated coactivator in human prostate cells. J Biol Chem. 1999;274(32):22373–22379
  126. Fujimoto N, Yeh S, Kang HY, et al. Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J Biol Chem. 1999;274(12):8316–8321
  127. Kang HY, Yeh S, Fujimoto N, et al. Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J Biol Chem. 1999;274(13):8570–8576
  128. Wang X, Yeh S, Wu G, et al. Identification and characterization of a novel androgen receptor coregulator ARA267-alpha in prostate cancer cells. J Biol Chem. 2001;276(44):40417–40423
  129. Fronsdal K, Engedal N, Slagsvold T, et al. CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1. J Biol Chem. 1998;273(48):31853–31859
  130. Bubulya A, Wise SC, Shen XQ, et al. c-Jun can mediate androgen receptor-induced transactivation. J Biol Chem. 1996;271(40):24583–24589
  131. Schneikert J, Peterziel H, Defossez PA, et al. Androgen receptor–Ets protein interaction is a novel mechanism for steroid hormone-mediated down-modulation of matrix metalloproteinase expression. J Biol Chem. 1996;271(39):23907–23913
  132. Hong H, Kohli K, Garabedian MJ, et al. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors. Mol Cell Biol. 1997;17(5):2735–2744
  133. Ikonen T, Palvimo JJ, Janne OA. Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. J Biol Chem. 1997;272(47):29821–29828
  134. Poukka H, Aarnisalo P, Karvonen U, et al. Ubc9 interacts with the androgen receptor and activates receptor-dependent transcription. J Biol Chem. 1999;274(27):19441–19446
  135. Lin HK, Yeh S, Kang HY, et al. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA. 2001;98(13):7200–7205
  136. bKaplan PJ, Mohan S, Cohen P, et al. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res. 1999;59(9):2203–2209
  137. Giovannucci E. Insulin-like growth factor-I and binding protein-3 and risk of cancer. Horm Res. 1999;51(Suppl 3):34–41
  138. Nickerson T, Pollak M, Huynh H. Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2, 3, 4 and 5. Endocrinology. 1998;139(2):807–810
  139. Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994;54(20):5474–5478
  140. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998;279(5350):563–566
  141. Stattin P, Bylund A, Rinaldi S, et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst. 2000;92(23):1910–1917
  142. DiGiovanni J, Kiguchi K, Frijhoff A, et al. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci USA. 2000;97(7):3455–3460
  143. Baserga R, Morrione A. Differentiation and malignant transformation: two roads diverged in a wood. J Cell Biochem. 1999;(Suppl 32–33):68–75
  144. Baserga R, Hongo A, Rubini M, et al. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta. 1997;1332(3):F105–F126
  145. Baserga R. The IGF-I receptor in cancer research. Exp Cell Res. 1999;253(1):1–6
  146. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth. Cancer Res. 1995;55(2):249–252
  147. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 2002;14(5):381–395
  148. Wu X, Senechal K, Neshat MS, et al. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA. 1998;95(26):15587–15591
  149. Wen Y, Hu MC, Makino K, et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 2000;60(24):6841–6845
  150. Sharma M, Chuang WW, Sun Z. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. J Biol Chem. 2002;277(34):30935–30941
  151. Graff JR, Konicek BW, McNulty AM, et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem. 2000;275(32):24500–24505
  152. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275(5308):1943–1947
  153. Cairns P, Okami K, Halachmi S, et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 1997;57(22):4997–5000
  154. Suzuki H, Freije D, Nusskern DR, et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 1998;58(2):204–209
  155. Whang YE, Wu X, Suzuki H, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA. 1998;95(9):5246–5250
  156. Vlietstra RJ, van Alewijk DC, Hermans KG, et al. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res. 1998;58(13):2720–2723
  157. Facher EA, Law JC. PTEN and prostate cancer. J Med Genet. 1998;35(9):790
  158. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95(1):29–39
  159. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411(6835):355–365
  160. Song K, Cornelius SC, Reiss M, et al. Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-beta by phosphatidylinositol 3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2. J Biol Chem. 2003;278(40):38342–38351
  161. Law BK, Chytil A, Dumont N, et al. Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Mol Cell Biol. 2002;22(23):8184–8198
  162. Huse M, Muir TW, Xu L, et al. The TGF beta receptor activation process: an inhibitor- to substrate-binding switch. Mol Cell. 2001;8(3):671–682
  163. Conery AR, Cao Y, Thompson EA, et al. Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta induced apoptosis. Nat Cell Biol. 2004;6(4):366–372
  164. Remy I, Montmarquette A, Michnick SW. PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3. Nat Cell Biol. 2004;6(4):358–365
  165. Arden KC. FoxO: linking new signaling pathways. Mol Cell. 2004;14(4):416–418
  166. Seoane J, Le HV, Shen L, et al. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell. 2004;117(2):211–223
  167. Birchenall-Roberts MC, Fu T, Bang OS, et al. Tuberous sclerosis complex 2 gene product interacts with human SMAD proteins. A molecular link of two tumor suppressor pathways. J Biol Chem. 2004;279(24):25605–25613
  168. Roberts AB. Molecular and cell biology of TGF-beta. Miner Electrolyte Metab. 1998;24(2–3):111–119
  169. Danielpour D, Sporn MB. Differential inhibition of transforming growth factor beta1 and beta 2 activity by alpha 2-macroglobulin. J Biol Chem. 1990;265(12):6973–6977
  170. Liu Q, Ling TY, Shieh HS, et al. Identification of the high affinity binding site in transforming growth factor-beta involved in complex formation with alpha 2-macroglobulin. Implications regarding the molecular mechanisms of complex formation between alpha 2-macroglobulin and growth factors, cytokines, and hormones. J Biol Chem. 2001;276(49):46212–46218
  171. LaMarre J, Hayes MA, Wollenberg GK, et al. An alpha 2-macroglobulin receptor-dependent mechanism for the plasma clearance of transforming growth factor-beta 1 in mice. J Clin Invest. 1991;87(1):39–44
  172. Wakefield LM, Smith DM, Flanders KC, et al. Latent transforming growth factor-beta from human platelets. A high molecular weight complex containing precursor sequences. J Biol Chem. 1988;263(16):7646–7654
  173. Ehrhart EJ, Segarini P, Tsang ML, et al. Latent transforming growth factor beta1 activation in situ: quantitative and functional evidence after low-dose gamma-irradiation. Faseb J. 1997;11(12):991–1002
  174. Barcellos-Hoff MH. Radiation-induced transforming growth factor beta and subsequent extracellular matrix reorganization in murine mammary gland. Cancer Res. 1993;53(17):3880–3886
  175. Ewan KB, Henshall-Powell RL, Ravani SA, et al. Transforming growth factor-beta1 mediates cellular response to DNA damage in situ. Cancer Res. 2002;62(20):5627–5631
  176. Flanders KC, Sullivan CD, Fujii M, et al. Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am J Pathol. 2002;160(3):1057–1068
  177. Danielpour D. Induction of transforming growth factor-beta autocrine activity by all-trans-retinoic acid and 1 alpha,25-dihydroxyvitamin D3 in NRP-152 rat prostatic epithelial cells. J Cell Physiol. 1996;166(1):231–239
  178. Murthy S, Weigel NL. 1alpha,25-dihydroxyvitamin D3 induced growth inhibition of PC-3 prostate cancer cells requires an active transforming growth factor beta signaling pathway. Prostate. 2004;59(3):282–291
  179. Lucia MS, Anzano MA, Slayter MV, et al. Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate. Cancer Res. 1995;55(23):5621–5627
  180. Kopp A, Jonat W, Schmahl M, et al. Transforming growth factor beta 2 (TGF-beta 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen. Cancer Res. 1995;55(20):4512–4515
  181. Liang Y, Eid MA, El Etreby F, et al. Mifepristone-induced secretion of transforming growth factor beta1-induced apoptosis in prostate cancer cells. Int J Oncol. 2002;21(6):1259–1267
  182. LaMarre J, Wollenberg GK, Gauldie J, et al. Alpha 2-macroglobulin and serum preferentially counteract the mitoinhibitory effect of transforming growth factor-beta 2 in rat hepatocytes. Lab Invest. 1990;62(5):545–551
  183. Adler HL, McCurdy MA, Kattan MW, et al. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol. 1999;161(1):182–187
  184. Shah AH, Tabayoyong WB, Kundu SD, et al. Suppression of tumor metastasis by blockade of transforming growth factor beta signaling in bone marrow cells through a retroviral-mediated gene therapy in mice. Cancer Res. 2002;62(24):7135–7138
  185. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA. 2003;100(15):8621–8623
  186. Wakefield LM, Roberts AB. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev. 2002;12(1):22–29
  187. Yang YA, Dukhanina O, Tang B, et al. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest. 2002;109(12):1607–1615
  188. Sehgal SN, Molnar-Kimber K, Ocain TD, et al. Rapamycin: a novel immunosuppressive macrolide. Med Res Rev. 1994;14(1):1–22
  189. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene. 2000;19(56):6680–6686
  190. Dutcher JP. Mammalian target of rapamycin inhibition. Clin Cancer Res. 2004;10(18):6382S–6387S
  191. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer. 2004;
  192. Sabers CJ, Martin MM, Brunn GJ, et al. Isolation of a protein target of the FKBP12–rapamycin complex in mammalian cells. J Biol Chem. 1995;270(2):815–822
  193. Lorenz MC, Heitman J. TOR mutations confer rapamycin resistance by preventing interaction with FKBP12–rapamycin. J Biol Chem. 1995;270(46):27531–27537
  194. Wang T, Li BY, Danielson PD, et al. The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors. Cell. 1996;86(3):435–444
  195. van der Poel HG, Hanrahan C, Zhong H, et al. Rapamycin induces Smad activity in prostate cancer cell lines. Urol Res. 2003;30(6):380–386

PII: S0959-8049(05)00050-X

doi: 10.1016/j.ejca.2004.12.027

European Journal of Cancer
Volume 41, Issue 6 , Pages 846-857 , April 2005

Article Tools